Chemotherapy: Open Access
Open Access
ISSN: 2167-7700
+44 1223 790975
ISSN: 2167-7700
+44 1223 790975
Ehab Mohammed Hassanen, Maha Lotfy Zamzam, Alaaeldeen Mahmoud Elbahai and Mohamed Omara Ibrahim Hussein
Background: Vinorelbine based and taxanes based chemotherapy are the most commonly used regimens given for parenchymal metastatic breast cancer. This study was held to compare the response of those regimens according to Response Evaluation Criteria In Solid Tumors (RECIST) in patients with parenchymal metastatic breast cancer in Suez Canal University Hospital, Clinical Oncology and Nuclear Medicine Department (SCUCON).
Aim: We performed this study to identify the best management to be given for patients with parenchymal metastatic breast cancer in (SCUCON).
Patients and Methods: This was a retrospective descriptive study that included all the patients with parenchymal (lung and/or liver) metastatic breast cancer (166 patients) treated in SCUCON between Jan 1995 and Jan 2011. The collected data included the medical history, clinical, laboratory, radiological and pathological data, the treatment received and follow-up for each patient, from files which are coded. Data was recorded without identifiable information, so the researchers asked for waiving of informed consent because it is a retrospective study.
Results: The study included 166 representing 12.6% of breast cancer patients. Over all comparison showed mild superiority of Navalbine based chemotherapy over Taxanes based chemotherapy. In metastatic breast cancer to liver, complete response was 25% with Navalbine compared to 54.5% with Taxanes. While in metastatic breast cancer to lung, complete response was 40.9% with Navalbine compared to only about 9% with Taxanes.
Conclusion: Navalbine based chemotherapy is more superior in patients with metastatic breast cancer to lung, while Taxanes based chemotherapy is more superior in patients with metastatic breast cancer to liver.